12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
In a complex and competitive market, minimising and mitigating risk in M&A is a key concern for deal...
Read More >
When I was a kid, I’d be passive-aggressive in the sense that I wouldn’t let people know how upset...
Read More >
We previously reported on the Bipartisan Budget Act (the “Budget Act”) hardship distribution rule ...
Read More >
Illinois has introduced new workplace privacy legislation governing the use of artificial intelligen...
Read More >
The SEC recently amended its disclosure requirements for historical and pro forma financial statemen...
Read More >
On May 21, 2020, the Securities and Exchange Commission adopted amendments to the rules that govern ...
Read More >